Lantern Pharma Inc (LTRN)

Dec 9, 2024, 8:15 AM EST - 5 weeks ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 3, 2024, 8:00 AM EST - 6 weeks ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Nov 26, 2024, 8:45 AM EST - 7 weeks ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 19, 2024, 8:00 AM EST - 2 months ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 8, 2024, 7:23 PM EST - 2 months ago

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 2 months ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 5, 2024, 8:00 AM EST - 2 months ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Oct 31, 2024, 8:00 AM EDT - 2 months ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 23, 2024, 8:45 AM EDT - 3 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 21, 2024, 8:00 AM EDT - 3 months ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 15, 2024, 9:07 AM EDT - 3 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Sep 23, 2024, 8:00 AM EDT - 4 months ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Aug 10, 2024, 4:01 AM EDT - 5 months ago

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 5 months ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 7, 2024, 9:31 AM EDT - 5 months ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 5, 2024, 8:00 AM EDT - 5 months ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 1, 2024, 8:00 AM EDT - 6 months ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Jul 10, 2024, 8:30 AM EDT - 6 months ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Jun 12, 2024, 7:30 AM EDT - 7 months ago

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

May 9, 2024, 4:02 PM EDT - 9 months ago

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 6, 2024, 3:00 AM EDT - 9 months ago

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 2, 2024, 7:30 AM EDT - 9 months ago

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Apr 24, 2024, 8:00 AM EDT - 9 months ago

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Apr 22, 2024, 8:12 AM EDT - 9 months ago

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Mar 18, 2024, 11:14 PM EDT - 10 months ago

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 4:02 PM EDT - 10 months ago

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Mar 15, 2024, 8:00 AM EDT - 11 months ago

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Mar 11, 2024, 7:30 AM EDT - 11 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Mar 5, 2024, 8:01 AM EST - 11 months ago

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Mar 4, 2024, 8:01 AM EST - 11 months ago

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

Feb 15, 2024, 8:01 AM EST - 1 year ago

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Jan 17, 2024, 7:30 AM EST - 1 year ago

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Nov 30, 2023, 8:00 AM EST - 1 year ago

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Nov 9, 2023, 5:28 AM EST - 1 year ago

Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 1 year ago

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

Sep 25, 2023, 8:30 AM EDT - 1 year ago

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

Sep 18, 2023, 9:00 AM EDT - 1 year ago

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin's Lymphomas

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting

Aug 28, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Aug 14, 2023, 8:30 AM EDT - 1 year ago

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

Aug 9, 2023, 8:25 PM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

Aug 2, 2023, 12:45 PM EDT - 1 year ago

RedChip Launches 'Small Stocks, Big Money' Podcast

BFRG RVPH STSS ZOM

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET

Jul 17, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

Jun 26, 2023, 8:30 AM EDT - 1 year ago

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin's Lymphomas

Jun 12, 2023, 8:30 AM EDT - 1 year ago

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors